Overview

Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.

Status:
Completed
Trial end date:
2008-12-31
Target enrollment:
Participant gender:
Summary
GSK1014802 is a use-dependent sodium channel blocker and an effective anticonvulsant in animal models. This study is being conducted to obtain information regarding the safety, tolerability and pharmacokinetics of repeated doses of GSK1014802 administered for up to 28 days in healthy male or female subjects. In addition, the effect of food on the pharmacokinetics of GSK1014802 will be investigated.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
GlaxoSmithKline
Treatments:
Diuretics, Potassium Sparing
Sodium Channel Blockers